Cardiovascular outcomes do not differ significantly by sex among patients receiving tirzepatide for obesity and heart failure.

For adults with T2D receiving SGLT2is, risk factors for ketoacidosis include high HbA1c, previous ketoacidosis, and recent hypoglycemia.

COVID-19 infection is associated with a lower risk for developing type 1 diabetes (T1D) in individuals younger than 30 years.

The FDA has granted Priority Review to Alexion's BLA for efzimfotase alfa, a biweekly enzyme replacement therapy for hypophosphatasia.

Deep-seated systemic and implicit racial biases within health care education, clinical decision-making, and diagnostic practices continue to drive persistent disparities in patient outcomes for people ...

The FDA has approved Kerendia (finerenone) to reduce UACR, which is expected to slow CKD progression in adults with type 1 diabetes.

A proposed machine learning framework for metabolic dysfunction-associated steatotic liver disease may improve personalized risk prediction.

Cultural stigma and sensationalized media narratives regarding GLP-1 RAs contribute to patient drug avoidance and treatment nonadherence.

All participating U.S. comprehensive cancer centers are experiencing a shortage of at least one anticancer agent, with more than 20 percent of centers currently ...

The SMFM released a special statement to offer a structured, multidisciplinary approach to managing sickle cell disease and vaso-occlusive crises during pregnancy.

Strict glycemic control failed to lower microvascular and macrovascular event rates, but increased hypoglycemia, in older adults with T2D.

High-risk proteomic signatures for cardiometabolic disease emerge during childhood but remain modifiable through adult GLP-1 therapy.